These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19996641)

  • 1. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient.
    Tombal B
    Urol Int; 2009; 83(4):373-8. PubMed ID: 19996641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complications of androgen deprivation therapy in prostate cancer.
    Schwandt A; Garcia JA
    Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy--managing side effects.
    Kabir S; Mancuso P; Rashid P
    Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
    Galvão DA; Taaffe DR; Spry N; Newton RU
    Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients.
    Moyad MA
    Urol Oncol; 2005; 23(1):56-64. PubMed ID: 15885584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
    Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U
    BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
    Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
    Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
    Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of side effects of androgen deprivation therapy.
    Grossmann M; Zajac JD
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):655-71, x. PubMed ID: 21889727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.